Treatment options are limited after the failure of first-and second-line treatments in patients with HER2⁺ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2⁺) mGC.

中文翻译：

---

阿帕替尼作为​​ HER2 阳性转移性胃癌的三线治疗：一项多中心单臂队列研究。

^{在 HER2 +}转移性胃癌 (mGC)患者的一线和二线治疗失败后，治疗选择受到限制。^{本研究旨在探讨阿帕替尼作为​​人上皮生长因子受体 2 阳性 (HER2 +} ) mGC患者三线治疗的疗效、安全性和预后因素。